These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22455376)

  • 1. Genetically encoded photo-cross-linkers map the binding site of an allosteric drug on a G protein-coupled receptor.
    Grunbeck A; Huber T; Abrol R; Trzaskowski B; Goddard WA; Sakmar TP
    ACS Chem Biol; 2012 Jun; 7(6):967-72. PubMed ID: 22455376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the allosteric modulation of CCR5 function by Maraviroc.
    Lagane B; Garcia-Perez J; Kellenberger E
    Drug Discov Today Technol; 2013; 10(2):e297-305. PubMed ID: 24050281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
    Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
    Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
    AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.
    Labrecque J; Metz M; Lau G; Darkes MC; Wong RS; Bogucki D; Carpenter B; Chen G; Li T; Nan S; Schols D; Bridger GJ; Fricker SP; Skerlj RT
    Virology; 2011 May; 413(2):231-43. PubMed ID: 21388649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Something new under the sun. Maraviroc poised for approval.
    Huff B
    GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
    [No Abstract]   [Full Text] [Related]  

  • 12. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
    MacArthur RD; Novak RM
    Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
    Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP
    J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
    McKinnell JA; Saag MS
    Curr Opin HIV AIDS; 2009 Nov; 4(6):513-7. PubMed ID: 20048719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc.
    Lemoine RC; Petersen AC; Setti L; Baldinger T; Wanner J; Jekle A; Heilek G; deRosier A; Ji C; Rotstein DM
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1674-6. PubMed ID: 20137937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
    Soulié C; Malet I; Lambert-Niclot S; Tubiana R; Thévenin M; Simon A; Murphy R; Katlama C; Calvez V; Marcelin AG
    AIDS; 2008 Oct; 22(16):2212-4. PubMed ID: 18832886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of viral entry.
    Melby T; Westby M
    Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.